Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $36.98 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

ucb sa - unsponsored adr (UCBJY) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $49.29
52 Week Low
05/26/15 - $34.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UCB SA - UNSPONSORED ADR (UCBJY)

Related News

No related news articles were found.

ucb sa - unsponsored adr (UCBJY) Related Businessweek News

No Related Businessweek News Found

ucb sa - unsponsored adr (UCBJY) Details

UCB S.A., a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The company’s product pipeline includes brivaracetam as an adjunctive therapy for epilepsy POS; Vimpat for various types of epilepsy; UCB4942 for drug resistant epilepsy; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 for immune-inflammatory diseases; UCB7665 for immunological diseases; and dapirolizumab pegol for systemic lupus erythematosus. The company has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,535 Employees
Last Reported Date: 02/28/15
Founded in 1928

ucb sa - unsponsored adr (UCBJY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ucb sa - unsponsored adr (UCBJY) Key Developments

UCB S.A. (ENXTBR:UCB) Seeking To Sell

UCB S.A. (ENXTBR:UCB) has decided to sell its stake for around $7.7 million.

UCB S.A. Presents at Citi European Healthcare Conference, Jun-15-2015

UCB S.A. Presents at Citi European Healthcare Conference, Jun-15-2015 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Antje Witte, Vice President of Investor Relations, Isabelle Ghellynck, Investor Relations Manager.

UCB Announces Sales Results for the First Quarter of 2015; Confirms Financial Outlook for 2015

UCB announced sales results for the first quarter of 2015. For the quarter, the company reported revenue of EUR 895 million, a plus of 19% driven by the strong growth of Cimzia®, Vimpat® and Neupro® with combined net sales of EUR 433 million, while Keppra® reached EUR 190 million, the four medicines together represent 70% of UCB's revenue in the first quarter 2015. The company also confirmed financial outlook for 2015. For 2015, the company expects the continued growth of Cimzia®, Vimpat®, Neupro® to drive overall company growth. 2015 revenue should reach approximately EUR 3.55 billion to EUR 3.65 billion; recurring EBITDA should increase to approximately EUR 710 million to EUR 740 million. Core earnings per share (EPS) are expected in the range of EUR 1.90 to EUR 2.05 based on an average of 193.7 million shares outstanding.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCBJY:US $36.98 USD 0.00

UCBJY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $82.02 USD +1.13
Grifols SA €36.27 EUR -0.58
Hospira Inc $88.95 USD +0.06
Lonza Group AG SFr.128.20 CHF -0.20
Sigma-Aldrich Corp $139.48 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation UCBJY Industry Range
Price/Earnings 100.0x
Price/Sales 3.5x
Price/Book 2.3x
Price/Cash Flow 56.8x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA - UNSPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at